Nikos Vasilakis

Our focus is to understand the mechanisms that allow zoonotic, sylvatic arthropod-borne viruses to jump species boundaries and cause disease. Shared lab account

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

Conducting real-time epidemiological research during a pandemic demands adaptability. In the AVISA study, we faced recruitment challenges, vaccination shifts, and logistical complexity. Progress relied on flexibility and coordination. resilient research requires rapid adaptation.

[Jochen Reiser MD PhD @JochenReiser]

In a disruptive environment, delay is the highest-risk strategy. Don’t wait for full clarity.
Another mistake is treating AI, workforce, and strategy as separate conversations. They are one and the same transformation.

[UTMB Provost's Office @UTMBProvost]

Congratulations to Dr. Shannan L. Rossi on being named the inaugural Associate Dean of Strategic Initiatives, @UTMBGSBS! We are grateful for her leadership as she helps advance the school’s strategic priorities and strengthen the impact of its academic and research programs.

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

Our new study presents an integrated pipeline for rapid epitope-based pan-alphavirus vaccine design, combining immunoinformatics, structural modeling, and experimental validation to identify broadly immunogenic candidates.
Congratulations to Alice and the entire team @afversiani

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

We report in Nature Medicine that the single-dose Butantan dengue vaccine showed 65% efficacy against symptomatic dengue and 80.5% protection against severe disease over 5 years, with a favorable safety profile in participants aged 2–59 in Brazil.

[Nikos Vasilakis @Vasilakis_Lab]

Αn important study long overdue!

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

Maternal dengue antibodies can have two effects in infants: early protection, followed by increased risk of severe disease between 5–12 months (antibody-dependent enhancement). In Brazil dengue rose sharply from 2000–2024, with peaks of severe risk at birth and around 7–8 months.

[Nikos Vasilakis @Vasilakis_Lab]

What a great day for the Houston Marathon. Great community of supporters, lots of fun and a nice cold weather. Congratulations to all runners! @utmbhealth @ASTMH @Rossi_viruslab

[Nikos Vasilakis @Vasilakis_Lab]

Great collaborative work. Congratulations to all team members for th hard work!

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

Intra-host population dynamics of chikungunya virus in humans and naturally infected Aedes mosquitoes reveal transmission-driven diversity https://t.co/eEmb8ubxts

just published!
@ACAV_ASTMH @AgenciaFAPESP @famerp @Vasilakis_Lab

[Nikos Vasilakis @Vasilakis_Lab]

Our recent work highlighted @Virology_FAMERP @Rossi_viruslab @ASTMH @sbviro @utmbhealth

[Viruses MDPI @VirusesMDPI]

Standardization of Quantitative Plaque-Based Viral Assays for Orthoflavivirus Cacipacoré

✍ by Saivish et al.

➡️ https://t.co/FJoWnpccTQ

[VignuzziLab @VignuzziLab]

Excellent seminar and motivational talk with Carla Saleh, her love for science radiates from her.

@SalehLabParis

[Nikos Vasilakis @Vasilakis_Lab]

a monumental effort led by Peter Simmonds & Jens Kuhn to reorganize the Family Flaviviridae based on analysis of RNA-directed RNA polymerase (RdRP) hallmark gene sequences is finally out. Enjoy reading! #ICTV, @ASTMH @utmbhealth @sbviro @

[Nikos Vasilakis @Vasilakis_Lab]

Delighted to see Marielena's manuscript on the "Standardization of Quantitative Plaque-Based Viral Assays for Orthoflavivirus Cacipacoré" published. A collaborative effort with colleagues on our drive to characterize a number of Brazilian neglected orthoflaviviruses.

[Nikos Vasilakis @Vasilakis_Lab]

We Look forward welcoming you on October 14th for Prof. Kim's webinar "Development of Vaccines Against Alphaviruses and Flaviviruses". Register: https://t.co/XJPtHiCFAq. @create_neo @ASTMH @ACAV_ASTMH @sbviro @Virology_FAMERP @Rossi_viruslab

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

A new ms is out!
Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon
Nice work with our friends from Fundacao Medicina Tropical Manaus

https://t.co/5lNqhAcILT

[Jochen Reiser MD PhD @JochenReiser]

Time to Re-think Strategies—And Refocus on Team Skills
I’ll explore how to make that shift in the unique context of academic healthcare during my upcoming C-Suite Assembly talk.
It’s time to build organizations where collaboration, adaptability, and shared purpose drive performance and innovation.

[Nikos Vasilakis @Vasilakis_Lab]

A great symposium with outstanding speakers. @sbviro @famerp @Virology_FAMERP @ACAV_ASTMH @ASTMH

[Mauricio Nogueira’s lab @Famerp @Virology_FAMERP]

Now is time fir Prof. Spilki

@sbviro @Vasilakis_Lab @famerp @Feevale @funfarme

[Nikos Vasilakis @Vasilakis_Lab]

RIP Ozzy. What a life! Thank you for the music! @sbviro @Virology_FAMERP @ASTMH @ACAV_ASTMH. You live for ever in our hearts

[Nikos Vasilakis @Vasilakis_Lab]

We look forward seeing you Aug 12 for our next webinar on Vector-Borne and Zoonotic Diseases. Dr Maringer will present "Virus-specific innate immune responses in Aedes aegypti". Register: https://t.co/slmPlJHE8z. @create_neo @ASTMH @sbviro @Virology_FAMERP @ACAV_ASTMH @utmbhealth

[Nikos Vasilakis @Vasilakis_Lab]

If you were not able to join us for Prof. Christofferson's @RC_Epi webinar, you may see it here https://t.co/lITCfpRk0w. @sbviro @utmbhealth @create_neo @ASTMH @ACAV_ASTMH @Virology_FAMERP